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INTRODUCTION
The endemic mycoses are a group of thermally dimorphic fungal pathogens occupying a 
specific geographic range. This geographic restriction occurs as a result of the unique 
environmental requirements that best promote sporulation for each species. In North 
America, the chief endemic mycoses are histoplasmosis, coccidioidomycosis, and 
blastomycosis.
GENERAL PRINCIPLES
Although they can cause serious infections, all 3 endemic mycoses are surprisingly rare in 
solid organ transplant (SOT) recipients (Table 1).1,2 A prospective study performed in 15 
transplant centers throughout the United States, including in high incidence areas, found 
only 33 cases of endemic mycoses among 16,806 patients who received a SOT during the 5-
year study period; 23 were histoplasmosis, 6 were coccidioidomycosis, and 4 were 
blastomycosis.1 By way of contrast, the incidence of invasive candidiasis in SOT recipients 
is approximately an order of magnitude higher.3 The incidence of the endemic mycoses is 
typically greatest in the 12 months after transplant, but the risk period extends for years 
thereafter.1,4–7
Histoplasmosis, coccidioidomycosis, and blastomycosis are all caused by environmental, 
soil-based fungi that are acquired chiefly, although not exclusively, through inhalation of 
conidia that have been aerosolized as a result of disturbance of the soil in which they are 
produced.8 The causative fungi are all thermally dimorphic, existing initially as a mold in 
the environment and then once in the body transforming themselves into either yeasts or, in 
the case of coccidioidomycosis, specialized structures called spherules.8,9 The fungi 
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typically establish themselves initially in the lung, although whether this is clinically 
apparent or not depends on a balance between the burden of disease and the state of the host 
immune system. Clinical disease can also occur when immunosuppression causes a loss of 
containment of a previously controlled infection, such as occurs from antirejection 
medication.10,11 Dissemination of the fungus can occur throughout the body if the immune 
system is unable to control the infection within the lungs. In the case of histoplasmosis and 
coccidioidomycosis, rare cases of disease acquired by an infected allograft have also been 
described; there are no reports of this with blastomycosis to date.1,12–15 There is typically a 
median of 2 weeks from symptoms onset until the diagnosis is ultimately made.5,7 In 
general, SOT recipients have been found to have more severe disease and a higher disease-
related mortality from the endemic mycoses than immunocompetent patients.2–6
Currently, no single diagnostic test has optimal sensitivity and specificity to reliably 
diagnose any of the endemic mycoses. Thus, in situations where histoplasmosis, 
blastomycosis, or coccidioidomycosis are considered, multiple different tests should be 
used. In general, microscopy, culture, antigen detection, and antibody assays are well-
established for all the endemic mycoses, although with important differences in their 
limitations that vary by species. Polymerase chain reaction testing is less well-established 
and often not commercially available, but offers the potential to complement the existing 
diagnostic armamentarium.
The agents used for treatment of the endemic mycoses are the polyenes (with liposomal 
amphotericin B now preferred) and the azoles (chiefly itraconazole or fluconazole). In 
general, mild infections can be treated with an azole alone, but more severe and/or 
disseminated disease (as occurs frequently in SOT recipients) requires initial therapy with 
amphotericin B and transition to an azole once clinical improvement occurs.16–18 Most SOT 
recipients with histoplasmosis, blastomycosis, and coccidioidomycosis generally require at 
least 12 months of treatment along with a temporary decrease in immunosuppressive 
regimens if possible. A risk of recrudescence or relapse exists for all of the endemic 




Mycelial growth in histoplasmosis is favored in soil in climates with moderate temperatures 
(between 15°C and 40°C), high relative humidity and a soil pH of greater than 5.5, although 
spores can survive for many years in less favorable environmental conditions.19 Bird and bat 
guano provides a high nitrogen, phosphorus, and organic matter content that is especially 
advantageous for histoplasmosis’ sporulation, allowing for mycelial growth even in the 
absence of soil.20 Typical risk factors for histoplasmosis acquisition in endemic areas 
include spelunking, farming, cleaning up bird droppings, refurbishing buildings that have 
been inhabited by birds or bats, such as barns, or other activities that disturb the soil.19,21
In the United States, studies from the 1950s to the 1970s identified areas of endemicity on 
the basis of positive histoplasmin skin test reactivity. Within North America, these areas are 
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centered around the Mississippi and Ohio River valleys (Fig. 1). Outside the United States, 
areas in Central and South America, and large parts of Africa and Australasia, are also 
considered endemic.21,22 However, it is likely that histoplasmosis can at least occasionally 
be acquired from a much wider range of environments than previously thought, especially in 
immunocompromised hosts.23,24
Pathogenesis
Infection with Histoplasma capsulatum is typically acquired when aerosolized micro-conidia 
are inhaled, because these infectious particles are small enough to reach the alveoli.10,21 
Once in the lung, the microcondia transform into yeasts and are phagocytosed by 
macrophages, within which they initially proliferate and may be transported throughout the 
reticuloendothelial system. Approximately 1 to 2 weeks are required before sufficient Th1 
cell-mediated immune response is generated to either kill or control the fungi in a quiescent 
state, driven by cytokines including interleukin-12, tumor necrosis factor-α, and interferon-
γ.25 This process may be impaired in SOT recipients. In addition, previous immunologic 
control of the fungus can be lost in patients who later receive immunosuppressant 
medication.10
Histoplasmosis in SOT recipients can thus be acquired in 1 of 2 main ways: as a new 
(primary) infection or via reactivation of a previously controlled infection. A surprisingly 
low baseline incidence in endemic areas (usually <0.5%) combined with dramatic increases 
seen during community outbreaks argue that primary infection may be the dominant mode 
of acquisition.5,26–28 Rarely, histoplasmosis can also rarely be transmitted via an infected 
allograft, although only a handful of confirmed cases of this have been published to date.
12,13
Clinical Presentation
In hosts with intact immunity, histoplasmosis is usually confined to the lungs, with a diverse 
array of presentations, including acute and chronic pneumonias, isolated pulmonary nodules, 
fibrosing mediastinitis, and broncholithiasis. In SOT recipients, however, presentation is 
mostly that of progressive disseminated disease.5,6,28 As may be expected from the 
pathogenesis of histoplasmosis, pulmonary involvement is extremely common (>80%, 
although this may be subclinical and detectable only on chest computed tomography scans), 
and thereafter the sites most likely to be involved are lymphoid-rich tissues: bone marrow, 
liver, spleen, and gastrointestinal tract.5,28 Typical symptoms include fever, fatigue, 
nonproductive cough, and diarrhea, and typical signs include hepatomegaly, splenomegaly, 
lymphadenopathy, and sometimes oral ulcers. Central nervous system (CNS) disease (<10%) 
and skin (<5%) involvement seem to be relatively uncommon. Almost any site can 
ultimately be involved however; rare cases of histoplasmosis in SOT recipients are reported 
involving the adipose tissue and tonsils.5,29 Patients can also present with an undifferentiated 
sepsis picture.
Diagnosis
No single test is sufficiently sensitive to reliably diagnose histoplasmosis in SOT recipients, 
so a strategy using multiple diagnostic modalities simultaneously is recommended (Table 2). 
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The single most sensitive test is a urine Histoplasma antigen test, which is positive in 
approximately 93% of cases when the newer generation assays are used. The test’s 
sensitivity correlates positively with disease severity.6,30 However, the assay’s specificity is 
limited by cross-reactions to antigens from Blastomyces, Paracoccidioides, and Penicillium 
species.30–32 Blood, bone marrow, and bronchoalveolar lavage cultures are all moderately 
sensitive in disseminated disease, but typically take several weeks to become positive.33 A 
bronchoscopic lung biopsy or cytology is positive in approximately three-quarters of cases.6 
Histoplasma capsulatum’s distinctive histologic appearance is that of a yeast, 2 to 5 μm in 
size, with narrow-based budding, often clustered within macrophages.34 The least sensitive 
test seems to be serum antibodies, with an overall sensitivity in SOT recipients of just 36% 
in 1 large series.6 Of note, false-positive Aspergillus galactomannan results have been 
reported in SOT recipients who had histoplasmosis.35 This finding should be borne in mind 
in SOT patients from histoplasmosis-endemic areas.
Treatment
Even without clear evidence of dissemination, SOT recipients with histoplasmosis should 
generally be treated as if they have disseminated disease.21 Liposomal amphotericin B is 
preferred over both itraconazole and amphotericin B deoxycholate for initial treatment in 
moderate and severe cases of disseminated disease.16,36,37 Liposomal amphotericin B has a 
lower rate of associated toxicities than the deoxycholate form, and is also possibly more 
potent in disseminated histoplasmosis.36 Liposomal amphotericin B should even be 
considered in cases complicated by renal disease despite the potential for additional 
nephrotoxicity; in many cases, as the disease comes under control, renal function improves 
rather than worsens.21 Liposomal amphotericin B is generally given for 1 to 2 weeks, 
followed by oral itraconazole for at least a year (Table 3). All azoles have some activity in 
histoplasmosis, although posaconazole is possibly the best alternative to itraconazole in 
cases of drug intolerance or clinical failure.21 Rising minimum inhibitory concentrations to 
both fluconazole and voriconazole have been observed while on therapy (whereas this has 
not been demonstrated with posaconazole), and there is limited clinical experience with 
isavuconazole.38 There is no role for echinocandin therapy in histoplasmosis.31
Once the diagnosis of histoplasmosis is made, immunosuppressive medication should be 
reduced, although the optimal timing and strategy in this regard is unknown. Azole treatment 
can probably be stopped after 12 months if there is no evidence of active infection. Ideally, 
the urine and blood antigen tests should be negative by that point, although they may remain 
positive at a low level for years after clinical resolution of disease. Therapy should not be 
prolonged merely because of this low-level antigenemia. After completion of treatment, 
long-term suppressive azole therapy in SOT recipients may be considered, but there is little 
evidence to endorse this practice, and the risk of disease relapse after completion of therapy 
is less than 5% when adequate initial therapy is given.6 In addition, in high-risk patients (eg, 
patients in whom no significant reduction of immunosuppression was possible), relapses can 
be screened for by serial urine antigen testing.16 Thus, chronic suppressive therapy may be 
unnecessary for the majority of SOT recipients.
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The mortality from histoplasmosis acquired after SOT is approximately 10%.1,6,28 In the 
largest study, 72% of the deaths occurred within 1 month after diagnosis, and on multivariate 
analysis those who died from histoplasmosis were statistically more likely to be older and to 
have had severe disease, as might be expected.6
BLASTOMYCOSIS
Epidemiology
A recent phylogenetic analysis has revealed that Blastomyces dermatitidis, the sole cause of 
blastomycosis, is in fact 2 distinct species, B dermatitidis and Blastomyces gilchristii.39 The 
natural habitat of Blastomyces is largely unknown, partly because, unlike other dimorphic 
fungi, it is extremely difficult to culture the organism from soil samples. Interesting new 
phylogeographic work has found a strong association of blastomycosis with freshwater 
basins, which complements earlier findings that suggested that Blastomyces conidiophores 
required exposure to water before their conidia could be dispersed by air currents.40,41 In 
North America, endemic regions seem to be the US and Canadian areas bordering the 
Mississippi, Ohio, Tennessee, and Nelson River drainage basins, and a small area in the 
northeast surrounding the St Lawrence River (see Fig. 1). A detailed history usually reveals 
occupational or recreational activities that have disrupted the soil in these regions, such as 
construction, boating, fishing, cutting trees, or clearing brush. As with all endemic mycoses, 
however, cases can occasionally be seen outside these endemic regions (see Table 1).42
Pathogenesis
In a similar manner to other endemic fungi, Blastomyces conidia must generally be inhaled 
to acquire the infection. Once inside the lung, the conidia transform into the yeast phase, and 
can survive within macrophages. Both innate and cell-mediated immunity play vital roles in 
controlling blastomycosis, whereas the humoral immune system plays no clear role.43 
Unlike histoplasmosis and coccidiomycosis, no cases of blastomycosis acquired via infected 
allograft have been reported.1
Clinical Presentation
In immunocompetent individuals, approximately one-half of blastomycosis infections are 
asymptomatic and, of the symptomatic cases, pulmonary infection occurs in approximately 
80% and disseminated disease occurs in 25% to 40%—a far higher rate than seen with other 
endemic mycoses.17,44 Interestingly, from the limited number of cases published to date, the 
chief difference in presentation among SOT recipients is not necessarily a greater propensity 
for disseminated disease, but rather more severe pulmonary disease, with a higher 
consequent mortality.2,3,7 Lung involvement in SOT recipients more frequently progresses to 
acute respiratory distress syndrome and respiratory failure. In disseminated cases, the same 
typical sites are involved as with immunocompetent individuals. The skin is the most 
frequently involved extrapulmonary site, although multiple pustules or ulcers are more 
common than the classic verrucous lesions seen in immunocompetent patients.45,46 Bone 
Nel et al. Page 5













(lytic lesions), genitourinary (prostatitis or epididymitis), and CNS (meningitis or abscess) 
involvement are the next most common manifestations.
Diagnosis
Blastomycosis has a distinctive appearance on histologic specimens, namely that of a large 
yeast, 8 to 15 μm in size, with broad-based budding and a thick refractile cell wall.34 This 
characteristic appearance permits a rapid diagnosis to be provisionally made directly from 
sputum, bronchoalveolar lavage specimens, and tissue biopsies. This property is especially 
useful considering the frequent involvement of the skin, which provides an easily accessible 
biopsy site. A definitive diagnosis requires culturing the organism, but like the other 
endemic fungi this usually takes 1 to 4 weeks. Blastomycosis antigen enzyme-linked 
immunoassay tests can be performed on urine, blood, and cerebrospinal fluid samples, with 
urine having the greatest sensitivity (76%–93%).47,48 Like the urine histoplasmosis antigen 
test, this also suffers from a lack of specificity, principally owing to cross-reaction with other 
endemic fungi.43,47 Unlike histoplasmosis and coccidiomycosis, commercially available 
serologic testing in blastomycosis has poor sensitivity and therefore little clinical usefulness.
49
Treatment
In immunocompetent patients, milder non-CNS forms of blastomycosis may be treated 
entirely with an azole, typically itraconazole. However, because of the greater propensity for 
severe disease, it is recommended that blastomycosis cases in SOT recipients generally be 
treated with amphotericin B for 1 to 2 weeks initially, or until improvement is noted.17,43 
Thereafter, as with histoplasmosis, approximately 12 months of oral itraconazole should be 
given. Itraconazole is probably more efficacious than fluconazole, and considerably more 
clinical experience exists with itraconazole than with any other of the azoles in the treatment 
of blastomycosis (see Table 3).50
Prognosis
The limited numbers of cases of blastomycosis in SOT recipients reported in the literature 
makes assessing outcomes with any precision difficult, but mortality in SOT recipients with 
blastomycosis seems to be in the 35% to 38% range (although the rate directly attributable to 
blastomycosis itself is likely closer to 25%).2,7 This mortality rate is higher than that seen in 
immunocompetent patients, though lower than seen in patients with malignancies or AIDS.7
COCCIDIODOMYCOSIS
Epidemiology
Coccidiodomycosis is caused by 1 of 2 species: Coccidioides immitis or Coccidioides 
posadasii.51 Unlike Histoplasma and Blastomyces, Coccidioides is found exclusively within 
in hot, dry climates, in arid and semiarid soil.52 Specifically, Coccidioides is found in the 
southwestern United States, in the San Joaquin Valley, southern California, Texas, Arizona, 
and New Mexico, together with northern Mexico and noncontiguous areas in South America 
(see Fig. 1).53,54 C immitis is found predominantly within California and C posadasii is 
found in the remainder of the endemic areas in the Western hemisphere. Drought conditions 
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are associated with a higher incidence of reported coccidioidomycosis the following year, 
possibly because Coccidioides is relatively more tolerant of such conditions than competing 
organisms, and because dry conditions favor spore distribution.54 In endemic areas, 
sandstorms, military exercises, and outdoor construction work are recognized risk factors for 
disease acquisition.55
Pathogenesis
Maturing mycelial cells develop within the soil into arthroconidia, which are prone to be 
aerosolized by air currents or other disruptions of the soil. When inhaled, the arthroconidia 
form unique structures called spherules. Each of these develops to contain viable spores that 
can form further spherules when the original spherule ruptures, thereby quickly generating 
an exponential increase in fungal burden if unchecked. T-cell immunity is the principal form 
of control required for coccidioidomycosis, which may otherwise spread to extrapulmonary 
locations. Disseminated coccidioidomycosis is associated with a failure to generate an 
interferon-γ–led delayed-type hyper-sensitivity response to coccidioidal antigens.56 In a 
similar manner to histoplasmosis and blastomycosis, coccidioidomycosis can either be 
acquired de novo or be reactivate from a dormant state if the patient loses prior immunologic 
control of the organism owing to immunosuppression.11 Rarely, coccidioidomycosis can be 
transmitted via infected allograft.14,15
Clinical Manifestations
In immunocompetent hosts, approximately 60% of disease is asymptomatic and the vast 
majority of the remainder manifests as isolated pulmonary disease, with only less than 0.5% 
of patients having disseminated infection.55 In immunocompromised hosts, such as SOT 
recipients, the rates of disease dissemination increase markedly, causing an increase in 
mortality and morbidity. Pulmonary disease mimics community-acquired pneumonia and 
can range from minimally symptomatic to fulminant disease. Apart from the lung, common 
sites for dissemination are the CNS, liver, spleen, kidney, skin, and joints.4,57
Diagnosis
The spherule is pathognomonic for coccidioidomycosis, and thus identification of it from 
any sample establishes the diagnosis. Coccidioides cultures readily on most media in 
approximately 1 week.4 Laboratory personnel should be warned that coccidioidomycosis is 
suspected, because biocontainment procedures are required for safety when working with 
cultures. In tissue samples, spherules may be surrounded by either a granulomatous or a 
suppurative inflammatory response.4 The sensitivity of serologic tests is lessened in SOT 
recipients, who may not mount as robust an antibody response.4,58 Furthermore, a detectable 
serologic response may take 3 or more weeks to develop, causing false-negative results in 
early infection. However, because antibody levels generally decrease to undetectable levels 
with successful clearance of infection, a positive result typically represents either recent or 
active infection.59 Overall, enzyme-linked immunoassays are more sensitive but less specific 
than immunodiffusion tests; thus, the immunodiffusion tests are often used as confirmation 
tests for positive enzyme-linked immunoassay results. Urine or serum antigen testing is 
insensitive but most likely to be positive in disseminated disease. Cross-reaction with 
Histoplasma antigen test occurs.60,61
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As with the treatment of other endemic fungi in SOT recipients, mild pulmonary forms of 
the disease can be treated with azoles alone, but severe or disseminated cases generally 
require intravenous amphotericin B therapy initially, followed by azole therapy for 
approximately 12 months (see Table 3). Fluconazole and itraconazole are the most 
commonly used azoles, with fluconazole generally being preferred on the basis of more 
reliable absorption and less severe drug–drug interactions. A randomized, controlled trial 
comparing the 2 azoles failed to find a statistically significant difference in clinical response 
or relapse rate between them, although there was a trend toward itraconazole superiority.62
Fluconazole is the recommended first-line treatment for CNS infections, in contrast with 
histoplasmosis and blastomycosis, where the initial treatment for infections involving the 
CNS should be with amphotericin B. Immunosuppression should be lessened when possible, 
at least until the infection has begun to improve.59 The risk of recrudescent infection in SOT 
recipients with evidence of prior coccidioidomycosis may be substantial, and is far higher 
than seen with the other endemic mycoses.4,57,59 Thus, patients with a history of 
coccidioidomycosis should receive preemptive therapy after transplantation. Many experts 
also tend to preemptively treat all SOT recipients in endemic areas, regardless of the 
evidence for prior coccidioidomycosis.59 In either case, the usual duration of therapy is 6 to 
12 months. Furthermore, after successful treatment of SOT recipients, indefinite secondary 
prophylaxis with fluconazole is often necessary for as long as the patient takes 
immunosuppressive medications, because the rate of relapse is otherwise unacceptably high.
Prognosis
Although heterogeneous, the mortality rate in SOT recipients who develop 
coccidioidomycosis is substantial, and higher than seen with the other endemic mycosis. 
Early reports from the 1980s showed mortality rates of up to 62%, and a large-scale study 2 
decades later highlighted a 43% mortality attributable to coccidioidomycosis.1,4 Mortality 
rates are higher with disseminated disease than localized pulmonary disease.
TREATMENT ISSUES IN SOLID ORGAN TRANSPLANT RECIPIENTS
The primary agents available to treat the endemic mycoses are amphotericin B and the 
triazole antifungals. The echinocandins have poor in vitro activity against the dimorphic 
fungi and should not be considered as treatment options for them.16,17,59,63 Amphotericin B 
is only available intravenously, in either a deoxycholate or a liposomal form. When the drug 
is required, the liposomal formulation is preferred owing to its lower toxicity, particularly 
nephrotoxicity. In a randomized controlled trial of disseminated histoplasmosis in patients 
with AIDS, there was also a trend toward a higher clinical success rate and a lower mortality 
rate with the liposomal amphotericinB.36 Common side effects include nephrotoxicity, 
hypokalemia, and hypomagnesemia, as well as infusion-related chills. Severe disease from 
the endemic mycoses is often accompanied by a degree of renal impairment, but renal 
dysfunction should not necessarily dissuade clinicians from using amphotericin B, because it 
is preferred over the azoles in most cases of severe disease.16–18,21 Although the CNS 
penetration of amphotericin B is poor (<3%), amphotericin B has demonstrable efficacy and 
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is recommended first-line therapy for meningitis in both histoplasmosis and blastomycosis, 
although not coccidioidomycosis.16–18
Of the triazoles, the bulk of clinical experience lies with the first-generation agents, 
itraconazole and fluconazole. Voriconazole, posaconazole, and isavuconazole are less well-
studied despite their demonstrable in vitro activity, and their clinical evidence base primarily 
consists of small case series, often as salvage therapy, and with varying degrees of success.
28,64–67 Fluconazole has oral bioavailability of more than 90%, and absorption is not 
significantly affected by food or gastric acidity.68 The reliability of its absorption precludes 
the need to check plasma levels routinely. Fluconazole has the best CNS penetration of any 
of the available antifungal drugs (approximately 75%) and is used as an agent of first choice 
for coccidioidomycosis meningitis.18,69
Itraconazole is available both as a capsule or a solution. The solution formulation is 
preferred because of greater bioavailability, although gastrointestinal tolerability can be 
more problematic. Importantly, instructions to maximize bioavailability are opposite 
depending on the formulation. Food and an acidic gastric pH improve absorption of the 
capsule form of the drug (and so proton pump inhibitors, H2-antagonists, and antacids are 
contraindicated, whereas acidic cola beverages can improve absorption).70,71 By contrast, 
the oral solution is best absorbed on an empty stomach, and gastric pH has no effect.72 The 
erratic absorption of either form of the drug makes checking blood levels mandatory.73 A 
further important limitation of itraconazole is its poor CNS penetration, although successful 
treatment of meningitis is nonetheless achievable.69 Despite these disadvantages, 
itraconazole seems to be more efficacious than fluconazole in histoplasmosis and possibly in 
blastomycosis as well, accounting for its preference as the azole of choice for these 
conditions.50,74
Drug–drug interactions between commonly used immunosuppressive medications in SOT 
recipients and the antifungal medications discussed are essentially limited to the triazole 
class. These agents all target the fungal cytochrome P450-dependent enzyme lanosterol 14-
α-demethylase, thereby inhibiting fungal ergosterol production.75 However, all the azoles 
have varying degrees of affinity for various human cytochrome P450 enzyme system 
isoforms as well, and this property accounts for the bulk of the drug–drug interactions 
witnessed.76 In general, fluconazole has the least potent inhibition of cytochrome P450, and 
thus the fewest drug–drug interactions. The other mechanism of drug–drug interactions is 
via P-glycoprotein, an efflux pump for xenobiotics, which the triazoles similarly can inhibit 
and/or be a substrate of.76,77
It takes approximately 1 week after starting a triazole antifungal for the full effect of the 
enzyme inhibition to be felt. Conversely, when the triazole therapy is discontinued, the 
enzyme inhibition can last for up to a month thereafter.76 Close attention to azoles and 
immunosuppressive drug levels and dosage adjustments should be taken, particularly around 
these times. The effects of the antifungal drugs on commonly used immunosuppressive 
medications are summarized in Table 4. In general, drug levels of the calcineurin inhibitors 
(eg, tacrolimus) and mammalian target of rapamycin inhibitors (eg, sirolimus) almost always 
require dose reduction when triazoles are used. Of the listed antifungals, only isavuconazole 
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has been documented to alter mycophenolate levels. The data for increased prednisone 
exposure with azoles that are strong CYP3A4 inhibitors (itraconazole, voriconazole, 
posaconazole, and ketoconazole) are contradictory, and so monitoring for steroid side effects 
is recommended.78–81 There is no evidence of significant drug–drug interactions with 
prednisone and any of the other antifungals.
Reductions in immunosuppressive drug exposure can cause an immune reconstitution 
syndrome (IRS) with any of the endemic fungi. This syndrome is manifest by an 
immunologically mediated worsening of the symptoms and signs of the infection, and may 
be hard to distinguish from treatment failure.82 Clues to IRS include clinical deterioration 
despite adequate antifungal therapy, a failure to culture viable organisms from involved body 
sites, and stable or decreasing antigen levels for the endemic mycoses despite the clinical 
worsening.83 Management is on a case-by-case basis, and depends on delicately navigating 
the trade-off between the need to control the infection and to maintain an adequate level of 
immunosuppression to prevent organ rejection. Mild cases of IRS usually settle without 
intensifying immunosuppression, but IRS reactions can be life threatening, especially if they 
occur in sites such as the CNS, and these more severe instances usually mandate temporarily 
increasing the level of immunosuppression again.
PROPHYLAXIS REGIMENS IN SOLID ORGAN TRANSPLANT RECIPIENTS: 
AN UNRESOLVED ISSUE
A donor known with active disease with any of the endemic fungi is not considered a 
suitable candidate until (in the case of living donors) several months of therapy have 
controlled the infection.84 Nonetheless, active donor infection is sometimes only discovered 
after transplantation has occurred, in which case primary prophylaxis of the recipient is 
indicated (Table 5). The other definite indication for peritransplant prophylaxis is in SOT 
recipients with evidence of prior coccidioidomycosis. This evidence may include positive 
serologic tests or thin-walled cavities seen on chest radiographs or computed tomography 
scans. Equivocal cases required specialist assessment, although many experts give 
prophylaxis to all SOT recipients if they reside in a coccidioidomycosis-endemic area, 
regardless of prior coccidioidomycosis or not.59 There is only limited evidence for this 
practice, however. Primary prophylaxis in patients living in areas endemic for histoplasmosis 
or blastomycosis, and secondary prophylaxis in patients with a history of prior 
histoplasmosis or blastomycosis is probably unnecessary. This probably includes patients 
living in endemic areas who have computed tomography evidence of calcified granulomas in 
lungs, liver, spleen, lymph nodes, or other organs, because the risk of reinfection in this case 
seems low to nonexistent.16,26,85
There is a similar lack of definitive evidence to guide secondary prophylaxis in SOT 
recipients after completion of a treatment course. The relapse rate after treatment completion 
in coccidioidomycosis is particularly high in SOT recipients, and so consensus opinion is 
that all such patients should receive life-long secondary prophylaxis.59 The role of 
secondary prophylaxis for histoplasmosis and blastomycosis is less clear, and should 
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probably be limited to cases at high risk of relapse only (see Table 5).16,84 These high-risk 
scenarios would include patients in whom immunosuppression was not able to be lessened.
SUMMARY
Histoplasmosis, blastomycosis, and coccidioidomycosis are all relatively rare in SOT 
recipients, even those from endemic areas. However, they are more difficult to diagnose than 
many other infections that plague this population and can cause significant morbidity and 
mortality if they are not identified early. Therapy for the endemic mycoses is typically given 
for at least a year and is frequently complicated by drug–drug interactions between the 
triazoles and antirejection medications that requires close monitoring of immunosuppressive 
drug levels both when the triazoles are started and when they are stopped again after 
treatment completion.
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• Endemic mycoses are thermally dimorphic fungal pathogens occupying a 
specific geographic range.
• Histoplasmosis, coccidioidomycosis, and blastomycosis are the chief endemic 
mycoses in North America.
• Infections with endemic mycoses are uncommon, but can cause serious 
infection in solid organ transplant recipients.
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Geographic distribution of endemic fungal infections in the North America. (From Ryan KJ. 
The systemic fungal pathogens: cryptococcus, histoplasma, blastomyces, coccidioides, 
paracoccidioides. In: Ryan KJ, editor. Sherris medical microbiology. 7th edition. New York: 
McGraw-Hill; 2018. p. 750; with permission.)
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Table 2
Approximate sensitivities of histoplasmosis diagnostic tests in solid-organ transplant recipients





Bronchoalveolar lavage culture 60–72
Lung biopsy or cytology 77
Data from Refs.2,5,6,28,86
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Table 3
Typical therapeutic regimens for endemic fungi in SOT recipients
Mild Disease Severe Disease CNS Disease
Histoplasmosis Itraconazole 200 mg
every 8 hours for 3 d
and then twice daily
for 12 mo
Liposomal amphotericin
B (3 mg/kg)for 1–2 wk
then itraconazole







daily for 12 mo
Blastomycosis Itraconazole 200 mg
every 8 hours for 3 d
and then twice daily
for 12 mo (but
consider treating as





B (3 mg/kg)for 1–2 wk
then itraconazole




4–6 wk then a




400 mg/d for at least
12 mo
Liposomal amphotericin
B (5 mg/kg) for 1–2 wk
then fluconazole






Abbreviations: CNS, central nervous system; SOT, solid organ transplantation.
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Table 5






Histoplasmosis Donor with localized pulmonary
disease: itraconazole 200 mg once or
twice daily for 3–6 mo
Donor with disseminated disease:
itraconazole 200 mg once or twice
daily for 12 mo84
Not routinely indicated. Can
monitor urine antigen level
every 3 mo to determine
need. If required, consider
itraconazole 200 mg/d.16,84
Blastomycosis Donor with localized pulmonary
disease: itraconazole 200 mg once or
twice daily for 3–6 mo
Donor with disseminated disease:
itraconazole 200 mg once or twice
daily for 12 mo
Not routinely indicated. If
required, consider
itraconazole 200 mg/d.17
Coccidioidomycosis Donor with isolated pulmonary disease:
fluconazole 400 mg/d for 3–12 mo
(non-lung recipients) or lifelong (lung
recipients).
Donor with positive serology or
extrapulmonary disease: fluconazole
400 mg/d lifelong.84
Recipient with positive serology or
history of coccidioidomycosis:
fluconazole 200 mg/d for 6–12 mo.
Recipient living in a
Coccidioides-endemic area:
fluconazole 200 mg/d for 6–12 mo.59
Fluconazole 400 mg/d
indefinitely.59
Abbreviation: SOT, solid organ transplantation.
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